Endowed Professor of Health Sciences, Chair

Dr. Paula Deming received her B.S. and M.S. degrees in medical technology from the University of Vermont and earned a doctoral degree in molecular pathology from the University of North Carolina at Chapel Hill. She is currently an associate professor, endowed professor of Health Sciences and chair of the Department of Medical Laboratory and Radiation Sciences. Dr. Deming actively engages students in her research and teaches courses within the Medical Laboratory Science undergraduate and graduate programs.

Research and/or Creative Works

Dr. Deming’s area of expertise is in the area of molecular pathogenesis, with emphasis on the regulation of cell cycle and cell death programs, protein kinase signaling networks, and cellular migration.  Her research aims to explore molecular mechanisms of signal transduction, with the goal of identifying biomarkers and new therapeutic targets for human diseases such as cancer. The Deming laboratory uses in vitro and cell culture model systems along with a variety of cell biological and biochemical techniques to address important and novel questions in the field.

Dr. Deming actively engages students in her research and teaches courses within the Medical Laboratory Science undergraduate and graduate programs.

Publications

Deming, Paula and Kurokawa, Manabu "Dismantling the Apoptotic Cell by Caspases". (March 2017) In: eLS. John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0021564.pub2

Weir, ME, Mann, JE, Corwin, T, Fulton, ZW, Hao, JM, Maniscalco, JF, Kenney, MC, Roman Roque, KM, Chapdelaine, EF, Stelzl, U, Deming, PB, Ballif, BA, Hinkle, KL "Novel autophosphorylation sites of Src family kinases regulate kinase activity and SH2 domain-binding" (2016) FEBS Letters Apr;590(8):1042-52.

Deming, PB, Campbell, SL, Stone, JB, Rivard, RL, Mercier, AL, Howe, AK "Anchoring of Protein Kinase A by ERM (ezrin-radixin-moesin) proteins is required for proper netrin signaling through DCC (deleted in colorectal cancer)” January 9, 2015, doi:10.1074/jbc. M114.628644 jbc.M114.628644.

Kwolek, S and Deming, PB “Warfarin-induced hypersensitivity due to gluten sensitive enteropathy: A case study”, Clinical Laboratory Science (2012) 25(2):78-80.

Caldwell, GB, Howe, AK, Nickl, CK, Dostmann, WG, Ballif, BA, Deming, PB “Direct modulation of the protein kinase A catalytic subunit a by growth factor receptor tyrosine kinases”Journal of Cellular Biochemistry (2012) 113(1):39-48

Deming Paula, Kornbluth Sally. Dismantling the Apoptotic Cell. Encyclopedia of Life Sciences (ELS). John Wiley&Sons, Ltd: Chichester, September 2009.

Deming PB, Campbell SC, Baldor LC, Howe AK. PKA regulates PDGF-induced membrane ruffling and phosphatidylinositol dynamics. The Journal of Biological Chemistry. (2008)  Dec 12;283(50):35199-211 (Abstract)

Phalen T, Deming PB, Vikas A, Howe A, Jonsson T, Poole L, Neintz NH. Oxidation state governs structural transitions in peroxiredoxin II that correlate with cell cycle arrest and recovery. J. Cell Biol. (2007) 175:779-789. (Abstract)

Innes CL, Heinloth AN, Flores KG, Sieber SO, Deming PB, Bushel PR, Kaufmann WK, Paules RS. ATM Requirement in Gene Expression Responses to Ionizing Radiation in Human Lymphoblasts and Fibroblasts. Molecular Cancer Research. 2006; 4(3):197-207. (Abstract)

Deming PB, Rathmell JC. Mitochondria, cell death and B cell tolerance. Current Directions in Autoimmunity. 2006; 9:95-119. (Abstract)

Deming PB, Schafer ZT, Tashker JS, Potts MB, Deshmukh M, Kornbluth S. Bcr-Abl-mediated Protection from Apoposis Downstream of Mitochondrial Cytochrome C Release. Molecular and Cellular Biology. 2004; 24(23): 10289-10299. (Abstract)

Kaufmann WK, Campbell CB, Simpson DA, Deming PB, Filatov L., Galloway DA, Zhao XJ, Creighton AM, and Downes CS. Degradation of ATM-independent decatenation checkpoint function in human cells is secondary to inactivation of p53 and correlated with chro mosomal destabilization. Cell Cycle, 1. 2002; 210-219. (Abstract

Deming PB, Flores KG, Downes CS, Paules RS, and Kaufmann WK. ATR enforces the topoisomerase II-dependent G2 checkpoint through inhibition of Plk1 kinase. J.Biol.Chem.. 2002; 277, 36832-36838. (Abstract)

Deming PB, Cistulli CA, Zhao H, Graves PR, Piwnica-Worms H, Paules RS, Downes CS, and Kaufmann WK. The human decatenation checkpoint. Proc.Natl.Acad.Sci.U.S.A. 2001; 98, 12044-12049.

Paula Deming, Ph.D., MT (ASCP)

Areas of Expertise and/or Research

  • Cell signaling
  • Growth control pathways
  • Molecular pathology
  • Cancer biology

Funding

The Deming Laboratory's research is currently funded in part by the American Heart Association. Projects have also been partially funded through a Vermont Cancer Center Pilot Award and College of Nursing and Health Sciences Incentive Grants.

Education

  • Postdoctoral Training, Duke University Department of Pharmacology and Cancer Biology, Mentor: Dr. Sally Kornbluth
  • Postdoctoral Training, University of Vermont Department of Pharmacology, Mentor: Dr. Alan Howe
  • Ph.D, University of North Carolina-Chapel Hill, Dept. of Pathology and Laboratory Medicine, Mentor: Dr. William Kaufman
  • M.S., University of Vermont, Biomedical Technology
  • B.S., Medical Technology, University of Vermont

Contact

Phone:
  • (802) 656-2506
Office Location:

302B Rowell Building